Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
FANCE
REST API REST API
Homo sapiens
FANCE is differentially expressed in 207 experiments: 106 organism parts: placenta, skin, ... (104 more);, 156 disease states: normal, acute lymphoblastic leukemia, ... (154 more);, 68 cell types 270 cell lines 28 compound treatments and 64 other conditions.
Synonyms FACE, FAE
Orthologs FANCE (Gallus gallus)   Fance (Mus musculus)   fance (Danio rerio)   FANCE (Bos taurus)   Fance (Rattus norvegicus)   FANCE (Canis familiaris)   (Compare orthologs)
Gene Ontology Term protein binding, DNA repair, molecular_function, nucleus, nucleoplasm, Fanconi anaemia nuclear complex
UniProt Accession Q9HB96
Gene-Disease Assocation FANCONI ANEMIA, COMPLEMENTATION GROUP E; FANCE, FANCONI ANEMIA, COMPLEMENTATION GROUP A; FANCA
InterPro Term Fanconi_anaemia_gr_E_prot_C
Search EB-eye ENSG00000112039
Show more properties
Experimental Factors
Organism part

studied in E-AFMX-5, E-GEOD-6573, E-MEXP-1251, E-MTAB-24, E-MTAB-25, ... (19 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-18005, E-GEOD-4717, E-MTAB-62, ... (25 experiments)

Factor Value U/D Experiments
A549
2
E-GEOD-3202, E-GEOD-6013
MDA-MB-231
2
E-MTAB-62, E-TABM-420
BT474
1
2
E-MTAB-62, E-MEXP-440, E-MTAB-37
HepG2
1
E-GEOD-7307
HCC1599
1
E-MTAB-37
KATOIII
1
E-MTAB-37
264 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-MEXP-66, E-GEOD-4219, ... (37 experiments)

Factor Value U/D Experiments
CD105+ endothelial
1
2
E-AFMX-5, E-TABM-145
CD4+ T cell
2
E-GEOD-16190, E-MTAB-24
monocyte
1
2
E-GEOD-8286, E-MEXP-583, E-GEOD-995
n/a
1
E-MTAB-24
osteoblast
1
E-MEXP-1216
undifferentiated cell
1
E-GEOD-21668
62 more value(s).


Disease state

studied in E-GEOD-3307, E-MEXP-2069, E-GEOD-2549, E-MEXP-121, E-MTAB-62, ... (35 experiments)

Factor Value U/D Experiments
myeloma
2
E-MTAB-62, E-MTAB-372
breast carcinoma
2
E-MTAB-37, E-TABM-276
sarcoma
2
E-MTAB-37, E-GEOD-2719
acute lymphoblastic leukemia
2
E-MTAB-37, E-MTAB-62
cervical carcinoma
2
E-MTAB-62, E-MEXP-1331
choriocarcinoma
2
E-MTAB-62, E-MTAB-37
150 more value(s).


Compound treatment

studied in E-GEOD-1615, E-TABM-782, E-GEOD-5824, E-GEOD-3720, E-TABM-868, ... (18 experiments)

Factor Value U/D Experiments
none
1
7
E-GEOD-5824, E-MEXP-1601, E-MEXP-1958, E-TABM-868, E-GEOD-20719, ... (8 experiments)
interleukin-26 (Homo sapiens)
1
E-GEOD-7216
glutamine
1
E-MEXP-941
resveratrol
1
E-TABM-782
anti-CD3 antibody (clone:OKT3)
1
E-MEXP-1601
unknown
1
E-GEOD-7307
22 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd34
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-19420, E-GEOD-19743, E-GEOD-7967

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-4619, E-GEOD-2034, ... (6 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-20033, E-GEOD-3140, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MTAB-73, E-GEOD-17385, E-GEOD-20847, ... (8 experiments)

Genotype
studied in E-GEOD-3494, E-GEOD-17476, E-TABM-321, E-TABM-868, E-TABM-601, ... (6 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-13073, E-GEOD-6432, E-GEOD-5681, E-GEOD-20504, E-GEOD-19018, ... (9 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-MEXP-1290, E-MEXP-2069, E-GEOD-19330, ... (18 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12254

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-22056

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Material type
studied in E-MEXP-455, E-MEXP-1082, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-19703, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-22097, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246

Replicate
studied in E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, ... (7 experiments)

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-MEXP-973, E-GEOD-19246, E-GEOD-19815, E-GEOD-12198

Treatments comments 00 005
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-3494, E-TABM-43, E-GEOD-1561, E-GEOD-4922

Processing time: 0.411 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM